drugset / Trial / NCT00060112
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of gemcitabine by making cancer cells more sensitive to the drug. This phase I trial is studying the side effects and best dose of oblimersen and gemcitabine in treating patients with metastatic or unresectable solid tumors or lymphoma
Timeline
- Start
- 2003-03
- Primary completion
- 2009-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | oblimersen sodium | Antisense oligonucleotide | — | Intravenous |
Indications
Burkitt lymphoma
Hodgkins lymphoma
MALT lymphoma
adult T-cell leukemia/lymphoma
cancer of unknown primary site
chronic lymphocytic leukemia/small lymphocytic lymphoma
diffuse large B-cell lymphoma
large-cell immunoblastic lymphoma
mantle cell lymphoma
nodal marginal zone B-cell lymphoma
primary cutaneous T-cell lymphoma
splenic marginal zone lymphoma